Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Grant or award Director acquired 48,838 shares (grant or award)
  2. 4 Grant or award Atillasoy Ercem acquired 23,256 shares (grant or award)
  3. 4 Grant or award General Counsel acquired 23,256 shares (grant or award)
  4. 4 Grant or award Chief Executive Officer acquired 315,000 shares (grant or award)
  5. 4 Grant or award Chief Commercial Officer acquired 23,256 shares (grant or award)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market sale Director sold 65,725 shares at an average $7.48 ($491,850)
  9. 4 Open-market sale Chief Commercial Officer sold 516 shares at $9.01 ($4,651)
  10. 4 Open-market sale Chief Commercial Officer sold 15,322 shares at $8.32 ($127,525)
  11. 4 Open-market buy Director bought 5,000 shares at $8.87 ($44,350)
  12. 4 Open-market sale Atillasoy Ercem sold 4,639 shares at $8.24 ($38,248)
  13. 4 Open-market sale Director sold 17,100 shares at $8.01 ($136,889)
  14. 4 Open-market sale Chief Commercial Officer sold 4,656 shares at $8.75 ($40,752)
  15. 4 Open-market sale Chief Accounting Officer sold 1,563 shares at $8.75 ($13,680)
  16. 4 Open-market sale Director sold 6,450 shares at $8.75 ($56,454)
  17. 4 Open-market sale Chief Commercial Officer sold 514 shares at $17.06 ($8,770)
  18. 4 Open-market sale Chief Commercial Officer sold 15,203 shares at $21.13 ($321,262)
  19. 4 Open-market sale Chief Scientific Officer sold 20,988 shares at an average $22.18 ($465,559)
  20. 4 Open-market sale Director sold 800 shares at $24.77 ($19,812)

Page 13 of 19 · 363 filings